Literature DB >> 1826631

Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice.

N Takahashi1, P Brouckaert, W Fiers.   

Abstract

Multiple administration of sublethal doses of recombinant murine tumor necrosis factor (TNF), e.g., 2 micrograms i.p. twice daily for 4 to 6 consecutive days, produces tachyphylaxis to the anorectic effects of TNF and tolerance towards a lethal challenge with recombinant murine TNF. The objective of this study was to examine whether the antitumor efficacy of TNF was retained in mice made tolerant. We treated tolerant and nontolerant C57BL/6 mice bearing a syngeneic B16BL6 melanoma tumor with repeated administrations of recombinant murine TNF (5 to 12.5 micrograms/injection) alone or in combination with recombinant murine gamma-interferon (5,000 to 50,000 units/injection). When the paralesional administration route was used, the tolerance-inducing pretreatment protected mice against the lethal outcome of both the single and the combination treatments (100% versus 40% survival in the former case; 80% versus 0% survival in the latter case) and still allowed complete regression of the tumor. When the i.p. route of administration was used, the final outcome was less positive; nevertheless, a significant protection against the lethal effects of the treatment was achieved without reduction of the antitumor efficacy. It is concluded that the toxic and antitumor activities of TNF are not inevitably linked and that their separation is an achievable research and perhaps a clinical goal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826631

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Production of polyclonal antibodies to feline tumor necrosis factor.

Authors:  C M Otto; F Niagro; R A McGraw; C A Rawlings
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

2.  Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activities comparable to those of the wild type but with reduced systemic toxicity.

Authors:  R Lucas; B Echtenacher; E Sablon; P Juillard; S Magez; J Lou; Y Donati; F Bosman; A Van de Voorde; L Fransen; D N Männel; G E Grau; P de Baetselier
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

3.  High-level constitutive expression of alpha 1-acid glycoprotein and lack of protection against tumor necrosis factor-induced lethal shock in transgenic mice.

Authors:  C Libert; T Hochepied; F G Berger; H Baumann; W Fiers; P Brouckaert
Journal:  Transgenic Res       Date:  1998-11       Impact factor: 2.788

4.  The major acute-phase protein, serum amyloid P component, in mice is not involved in endogenous resistance against tumor necrosis factor alpha-induced lethal hepatitis, shock, and skin necrosis.

Authors:  W Van Molle; T Hochepied; P Brouckaert; C Libert
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

Review 5.  The central role of hypothalamic inflammation in the acute illness response and cachexia.

Authors:  Kevin G Burfeind; Katherine A Michaelis; Daniel L Marks
Journal:  Semin Cell Dev Biol       Date:  2015-11-03       Impact factor: 7.727

6.  The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.

Authors:  Katherine A Michaelis; Mason A Norgard; Xinxia Zhu; Peter R Levasseur; Shamilene Sivagnanam; Shannon M Liudahl; Kevin G Burfeind; Brennan Olson; Katherine R Pelz; Diana M Angeles Ramos; H Carlo Maurer; Kenneth P Olive; Lisa M Coussens; Terry K Morgan; Daniel L Marks
Journal:  Nat Commun       Date:  2019-10-15       Impact factor: 14.919

7.  Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

Authors:  J M Stouthard; H Goey; E G de Vries; P H de Mulder; A Groenewegen; L Pronk; G Stoter; H P Sauerwein; P J Bakker; C H Veenhof
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.